A "Crisp" New Play on the Biotech Sector

You are receiving this email because you signed up to receive True Market Insider. Unsubscribe Keep the emails you value from falling into your spam folder. Whitelist True Market Insider. Forgot your login information? Click here. A "Crisp" New Play on the Biotech Sector Perhaps no science has improved the human condition more than biotechnology. And in the 21st century, no aspect of modern life has benefited more from this relatively new science – the term was coined in 1919 by a Hungarian agricultural named Karl Ereky – than crop production. To a large extent, we have CRISPR to thank for that. Developed in 2012, CRISPR – an acronym for "clusters of regularly interspaced short palindromic repeats" – enables the precise editing of the DNA of living organisms. In simple terms, it works much the same way as editing a document on your computer. If you see a phrase you don't like, you just highlight and delete it. In the world of agriculture, you can use CRISPR to eliminate an undesirable trait in a crop plant in order to increase yield. With this technique, you simply "snip" the parts of a plant's DNA responsible for that trait and presto – that trait no longer exists. ========Recommended Link======== PUT $4,928 INTO YOUR POCKET EVERY WEEK This summer, change the way you trade forever. This free event will show you how you can turn just a few hundred dollars into a major income stream. Learn More... Want drought-resistant corn? Snip! Want to make your soybeans immune to blight? Snip! Want to create wheat that uses its own immune system to repel pests? Snip! Thanks to CRISPR, we will soon have: High oleic soybean oil with zero trans fat and 20% reduced saturated fat (which studies show can lower your risk of heart disease) Wheat that could produce flour with up to three times more dietary fiber (thereby improving digestion, lowering cholesterol and stabilizing glucose levels) Low lignin alfalfa to enhance the nutrition of dairy, hog and poultry herds (making for healthier forms of animal protein) Potatoes you can store in the refrigerator (making them last far longer after you buy them) Gluten reduced wheat (a Godsend to bread lovers with gluten sensitivities) CRISPR biotechnology is also providing alternatives to toxic chemicals for pest and disease control. As a result, were getting … Herbicide tolerant wheat (which makes weed management of wheat fields far easier and less costly) Corn, rice and wheat that's immune to powdery mildew disease (a disease that not only damages crops, but can cause a host of lung diseases if ingested) The ability to control and suppress the population of crop-ravaging insects (thus reducing or eliminating the need for toxic insecticides) As a result of the above, farmers are getting higher yields, lower overhead and making more money. Consumers benefit as well though getting food products with more nutrition, higher fiber and less gluten…all at a lower cost. CRISPR technology is also being used to bolster the immune systems of people in order to help them overcome a wide variety of diseases. According to Labiotech, a leading digital media source covering the European biotech industry, there are seven major diseases that are potential candidates for CRISPR-related treatments. These diseases include cancer. For example, CRISPR clinical trials are being run to test its effectiveness on advanced cases of esophageal cancer. The treatment involves extracting immune cells from a patient and using CRISPR to modify them so they're better able to battle circulating cancer cells. Efforts to treat blood disorders like sickle cell disease and beta-thalassemia are also undergoing CRISPR trials in the U.S. and Europe. These trials involve harvesting bone marrow stem cells and engineering them to produce fetal hemoglobin, which is better at carrying oxygen than adult hemoglobin. The scourge of genetic blindness is another mutation that scientists are aiming to treat with CRISPR. AIDS may also be treated in the future with CRISPR technology, which would involve cutting "hidden" DNA out of the virus that causes HIV. Another ailment that could benefit from CRISPR editing is muscular dystrophy, which scientists know is caused by mutations in the DMD gene responsible for letting muscles contract. CRISPR might also make it possible to remove gene sequences responsible for Huntington's Disease, a devastating neurodegenerative disorder. As you might imagine, CRISPR technology offers significant profit opportunities for biotech investors. One play I like is Calyxt (Nasdaq: CLXT), a Minnesota-based biotech small cap using CRISPR to improve the nutritional density of wheat, alfalfa and potatoes. The stock was selling for around $7.75 toward the end of 2019, but – like virtually every equity – took a nosedive in March after the coronavirus ran roughshod over the markets. Since then it's shot up over 150%, going from about $2.50 to $6.36, yesterday's close. A year ago it was trading for $12.90, and I believe it could easily return to that price in the next few weeks. That would represent a solid 106% gain. However, a word of caution... This stock is highly speculative and trades on small volume, typically about 96,000 shares a day. Therefore, it's volatile. So while I like the stock, I wouldn't go hog wild with it - maybe buy a couple of hundred shares or so. Since there are no options on it, you'd have to make a straight-up stock purchase. One more quick thing... If you haven't saved your seat in today's FREE investor briefing with Costas Bocelli... Go here now and sign up. Costas is going to discuss a strategy you can use to generate extra income this summer. That's it for this week. To your financial health, Doug Fogel Editor, True Market Insiders FREE EVENT:  "This is the perfect trading strategy at the perfect time." Go here to find out how you could bank thousands every week RECENT STORIES Want to Make Consistent Money in the Market? The Most Accurate Indicator You've Never Heard Of The Best Traders All Have This "Superpower" Before You "Double Down" on a Losing Stock, Do This Instead… Copyright  ©   2020  True Market Insiders, All rights reserved. Our mailing address is: 33 SE 8th St, Boca Raton, FL 33432 Want to change how you receive these emails? You can  update your preferences   or   unsubscribe from this list DISCLAIMER The information contained herein has been prepared without regard to any particular investor's investment objectives, financial situation, and needs.  Accordingly, investors should not act on any recommendation (express or implied) or information in this material without obtaining specific advice from their financial advisors and should not rely on information herein as the primary basis for their investment decisions. True Market Insiders LLC is not an investment advisor and is not licensed to give specific financial advice.   The chairman of True Market Insiders, Chris Rowe, is also the CEO, CIO and owner of Rowe Wealth Management LLC, which is not owned by and is not the owner of True Market Insiders. Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources believed to be reliable ("information providers").  However, such information has not been verified by True Market Insiders or the information provider and TMM and the information providers make no representations or warranties or take any responsibility as to the accuracy or completeness of any recommendation or information contained herein.  TMM and the information provider accept no liability to the recipient whatsoever whether in contract, in tort, for negligence, or otherwise for any direct, indirect, consequential, or special loss of any kind arising out of the use of this document or its contents or of the recipient relying on any such recommendation or information (except insofar as any statutory liability cannot be excluded).  Any statements nonfactual in nature constitute only current opinions, which are subject to change without notice.  Neither the information nor any opinion expressed shall constitute an offer to sell or a solicitation or an offer to buy any securities, commodities or exchange traded products.  This document does not purport to be complete description of the securities or commodities, markets or developments to which reference is made.   Unless otherwise stated, performance numbers are based on pure price returns, not inclusive of dividends, fees, or other expenses.  Past performance is not indicative of future results.  Potential for profits is accompanied by possibility of loss.    You should consider this strategy's investment objectives, risks, charges and expenses before investing.  The examples and information presented do not take into consideration commissions, tax implications, or other transaction costs.   The material has been prepared or is distributed solely for information purposes and is not a solicitation or an offer to buy any security or instrument or to participate in any trading strategy. Some performance information presented is the result of back-tested performance.  Back-tested performance is hypothetical (it does not reflect trading in actual accounts) and is provided for informational purposes to illustrate the effects of the True Market Insiders LLC strategy during a specific period.  The relative strength strategy is NOT a guarantee.  There may be times where all investments and strategies are unfavorable and depreciate in value.  Relative Strength is a measure of price momentum based on historical price activity.  Relative Strength is not predictive and there is no assurance that forecasts based on relative strength can be relied upon.   Back-tested performance results have certain limitations.  Such results do not represent the impact of material economic and market factors might have on an investor's decision making process if the investors were actually managing money.  Back-testing performance also differs from actual performance because it is achieved through retroactive application of a model investment methodology designed with the benefit of hindsight.  True Market Insiders believes the data used in the testing to be from credible, reliable sources, however; True Market Insiders makes no representation or warranties of any kind as to the accuracy of such data.  All available data representing the full platform of investment options is used for testing purposes.